¿Son las terapias biológicas las primeras modificadores de la enfermedad en la espondilitis anquilosante?

Sanmartí Sala, Raimon.
Reumatol. clín. (Barc.) ; 3(extr.2): 51-54, jul. 2007.
Artículo en Español | IBECS (España) | ID: ibc-78009

Documentos relacionados

  1. New developments in ankylosing spondylitis-status in 2021.
  2. Golimumab, the newest TNF-α blocker, comes of age.
  3. Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries.
  4. Persistence and treatment-free interval in patients being prescribed biological drugs in rheumatology practices in Germany.
  5. Efficacy of TNF-α Inhibitors in the Treatment of nr-axSpA: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials.
  6. Sex Differences in the Treatment of Psoriatic Arthritis: A Systematic Literature Review.
  7. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs.
  8. Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta-analysis.
  9. Clinical remission of psoriatic arthritis in patients receiving continuous biological therapies for 1 year: the experience of an outpatient dermatological clinic for psoriasis.
  10. Emerging drugs for psoriatic arthritis.